Maria L. Ascierto, Ph.D. Saint John's Cancer Institute, top tier providence 131

Saint John's Cancer Institute's Director of Translational Immunology, Maria L. Ascierto, Ph.D. Contact Dr. Ascierto via email or phone number.

Resolving Cancer Heterogeneity: - PDF Free Download

Funding the Best - Saint John's Health Center Foundation

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - Journal of Thoracic Oncology

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect

Maria Libera Ascierto on LinkedIn: Great news for UC patients presented @ ESMO 2023- almost got emotional…

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect

Melanoma/Skin Cancer Treatment Center - Santa Monica, CA

Oncology - European Medical Journal

Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy), Journal of Translational Medicine

Oncology - European Medical Journal

Antoni Ribas – UCLA Graduate Programs in Bioscience (GPB)

PDF) Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021